Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
NCT06810583Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- May 2025
- Primary completion
- Sep 2030
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalbavancin in bacterial infection, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Rate of bacterial bloodstream infection at Day 56. Started May 2025; status: recruiting.
02
Drugs
dalbavancin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06810583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810583.